Page last updated: 2024-12-11

3,5-dihydroxy-4'-methoxystilbene

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

4'-methoxyresveratrol: has anti-inflammatory effects in cell culture model [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID6255462
CHEMBL ID291501
CHEBI ID108593
SCHEMBL ID563262
SCHEMBL ID563261
MeSH IDM0404583

Synonyms (66)

Synonym
AC-7025
33626-08-3
BRD-K02671211-001-02-2
BSPBIO_003527
desoxyrhapontigenin
bml 233
SDCCGMLS-0066773.P001
deoxyrhapontigenin
3,5-dihydroxy-4'-methoxystilbene
dhms cpd
SPECTRUM5_000570
QTL1_000070
NCGC00094628-01
NCGC00094628-02
CHEBI:108593
e 5-[2-(4-methoxy-phenyl)-vinyl]-benzene-1,3-diol
trans-3,5-dihydroxy-4''-methoxystilbene
5-[(e)-2-(4-methoxy-phenyl)-vinyl]-benzene-1,3-diol
(e)-3,5-dihydroxy-4''-methoxystilbene
5-(4-methoxystyryl)benzene-1,3-diol
3,5-dihydroxy-4''-methoxystilbene
13e-3,5-dihydroxy-4''-methoxystilbene
bdbm50085541
5-[2-((e)-4-methoxy-phenyl)-vinyl]-benzene-1,3-diol
5-[2-(4-methoxy-phenyl)-vinyl]-benzene-1,3-diol
resveratrol 4'-methyl ether
CHEMBL291501 ,
4'-methoxyresveratrol
5-[(e)-2-(4-methoxyphenyl)ethenyl]benzene-1,3-diol
A821880
5-[2-(4-methoxyphenyl)vinyl]benzene-1,3-diol;(e)-5-(4-methoxystyryl)benzene-1,3-diol
1,3-benzenediol, 5-[2-(4-methoxyphenyl)ethenyl]-
65728-21-4
S3939
CCG-38350
(e)-5-(4-methoxystyryl)benzene-1,3-diol
AKOS015915073
SCHEMBL563262
SCHEMBL563261
4'-o-methylresveratrol
1,3-benzenediol, 5-[(1e)-2-(4-methoxyphenyl)ethenyl]-
4-methoxyresveratrol
mfcd12407152
3,5-dihydroxy-4'-methoxy-trans-stilbene
bml-233
IHVRWFJGOIWMGC-NSCUHMNNSA-N
SR-05000002490-1
sr-05000002490
5-[(e)-2-(4-methoxyphenyl)vinyl]benzene-1,3-diol
DS-15252
desoxyrhaponigenin
trans-3,5-dihydroxy-4'-methoxystilbene
unii-ru7rry3ruw
ru7rry3ruw ,
Q17299987
BRD-K02671211-001-03-0
HY-N2485
CS-0022756
(e)-5-(4-methoxystyryl)benzene-13-diol
(e)-3,5-dihydroxy-4'-methoxystilbene
1,3-benzenediol, 5-(2-(4-methoxyphenyl)ethenyl)-, (e)-
3,5-stilbenediol, 4'-methoxy-, (e)-
5-((1e)-2-(4-methoxyphenyl)ethenyl)-1,3-benzenediol
1,3-benzenediol, 5-[(e)-2-(4-methoxyphenyl)ethenyl]-
DTXSID101031720
5-[2-(4-methoxyphenyl)ethenyl]-1,3-benzenediol

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" The pharmacokinetic profiles of DRG were subsequently examined in Sprague-Dawley rats."( Quantification of desoxyrhapontigenin (4-methoxyresveratrol) in rat plasma by LC-MS/MS: Application to pre-clinical pharmacokinetic study.
Chen, H; Dai, Y; Lin, HS; Ong, PS; Tan, ALC; Wu, J; Xiang, X, 2018
)
0.48

Bioavailability

ExcerptReferenceRelevance
" These results serve to highlight the contrasting effects on different activities brought about by methoxylation, which is widely employed as a structural modification approach to improve potency and bioavailability of resveratrol."( Methoxylation of resveratrol: effects on induction of NAD(P)H quinone-oxidoreductase 1 (NQO1) activity and growth inhibitory properties.
Go, ML; Zhang, W, 2011
)
0.37
" However, the methylated resveratrol analogs exhibit better bioavailability as they are more easily transported into the cell and more resistant to degradation."( Biosynthesis of methylated resveratrol analogs through the construction of an artificial biosynthetic pathway in E. coli.
Choi, O; Hong, YS; Hwang, BY; Jang, JH; Kang, SY; Kim, CY; Lee, JK, 2014
)
0.4
" After oral administration of DRG fully solubilized by 2-hydroxypropyl-β-cyclodextrin (HP-β-CD), the plasma profiles of DRG were highly erratic with a low absolute bioavailability (F < 9."( Quantification of desoxyrhapontigenin (4-methoxyresveratrol) in rat plasma by LC-MS/MS: Application to pre-clinical pharmacokinetic study.
Chen, H; Dai, Y; Lin, HS; Ong, PS; Tan, ALC; Wu, J; Xiang, X, 2018
)
0.48
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (12)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency22.38720.177814.390939.8107AID2147
TDP1 proteinHomo sapiens (human)Potency3.60190.000811.382244.6684AID686978; AID686979
polyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)Potency19.95261.000012.232631.6228AID1452
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency2.48030.00798.23321,122.0200AID2546; AID2551
lamin isoform A-delta10Homo sapiens (human)Potency11.22020.891312.067628.1838AID1487
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Cytochrome P450 1A1Homo sapiens (human)Ki0.16000.01200.94693.8000AID1452982
Neuronal acetylcholine receptor subunit alpha-4Rattus norvegicus (Norway rat)IC50 (µMol)19.60000.00030.30952.3000AID370920
Neuronal acetylcholine receptor subunit beta-2Rattus norvegicus (Norway rat)IC50 (µMol)19.60000.00030.32092.3000AID370920
Prostaglandin G/H synthase 1Homo sapiens (human)IC50 (µMol)25.80000.00021.557410.0000AID370919
Prostaglandin G/H synthase 2Homo sapiens (human)IC50 (µMol)19.60000.00010.995010.0000AID370920
Cytochrome P450 1B1Homo sapiens (human)Ki2.06000.00300.97417.4600AID1452983
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (141)

Processvia Protein(s)Taxonomy
cellular response to organic cyclic compoundCytochrome P450 1A1Homo sapiens (human)
response to hypoxiaCytochrome P450 1A1Homo sapiens (human)
long-chain fatty acid metabolic processCytochrome P450 1A1Homo sapiens (human)
lipid hydroxylationCytochrome P450 1A1Homo sapiens (human)
fatty acid metabolic processCytochrome P450 1A1Homo sapiens (human)
steroid biosynthetic processCytochrome P450 1A1Homo sapiens (human)
porphyrin-containing compound metabolic processCytochrome P450 1A1Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 1A1Homo sapiens (human)
steroid metabolic processCytochrome P450 1A1Homo sapiens (human)
estrogen metabolic processCytochrome P450 1A1Homo sapiens (human)
amine metabolic processCytochrome P450 1A1Homo sapiens (human)
response to nematodeCytochrome P450 1A1Homo sapiens (human)
response to herbicideCytochrome P450 1A1Homo sapiens (human)
ethylene metabolic processCytochrome P450 1A1Homo sapiens (human)
coumarin metabolic processCytochrome P450 1A1Homo sapiens (human)
flavonoid metabolic processCytochrome P450 1A1Homo sapiens (human)
response to iron(III) ionCytochrome P450 1A1Homo sapiens (human)
insecticide metabolic processCytochrome P450 1A1Homo sapiens (human)
dibenzo-p-dioxin catabolic processCytochrome P450 1A1Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 1A1Homo sapiens (human)
response to foodCytochrome P450 1A1Homo sapiens (human)
response to lipopolysaccharideCytochrome P450 1A1Homo sapiens (human)
response to vitamin ACytochrome P450 1A1Homo sapiens (human)
response to immobilization stressCytochrome P450 1A1Homo sapiens (human)
vitamin D metabolic processCytochrome P450 1A1Homo sapiens (human)
retinol metabolic processCytochrome P450 1A1Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 1A1Homo sapiens (human)
9-cis-retinoic acid biosynthetic processCytochrome P450 1A1Homo sapiens (human)
camera-type eye developmentCytochrome P450 1A1Homo sapiens (human)
nitric oxide metabolic processCytochrome P450 1A1Homo sapiens (human)
response to arsenic-containing substanceCytochrome P450 1A1Homo sapiens (human)
digestive tract developmentCytochrome P450 1A1Homo sapiens (human)
tissue remodelingCytochrome P450 1A1Homo sapiens (human)
hydrogen peroxide biosynthetic processCytochrome P450 1A1Homo sapiens (human)
response to hyperoxiaCytochrome P450 1A1Homo sapiens (human)
maternal process involved in parturitionCytochrome P450 1A1Homo sapiens (human)
hepatocyte differentiationCytochrome P450 1A1Homo sapiens (human)
cellular response to copper ionCytochrome P450 1A1Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 1A1Homo sapiens (human)
positive regulation of G1/S transition of mitotic cell cycleCytochrome P450 1A1Homo sapiens (human)
response to 3-methylcholanthreneCytochrome P450 1A1Homo sapiens (human)
prostaglandin biosynthetic processProstaglandin G/H synthase 1Homo sapiens (human)
response to oxidative stressProstaglandin G/H synthase 1Homo sapiens (human)
regulation of blood pressureProstaglandin G/H synthase 1Homo sapiens (human)
cyclooxygenase pathwayProstaglandin G/H synthase 1Homo sapiens (human)
regulation of cell population proliferationProstaglandin G/H synthase 1Homo sapiens (human)
cellular oxidant detoxificationProstaglandin G/H synthase 1Homo sapiens (human)
prostaglandin biosynthetic processProstaglandin G/H synthase 2Homo sapiens (human)
angiogenesisProstaglandin G/H synthase 2Homo sapiens (human)
response to oxidative stressProstaglandin G/H synthase 2Homo sapiens (human)
embryo implantationProstaglandin G/H synthase 2Homo sapiens (human)
learningProstaglandin G/H synthase 2Homo sapiens (human)
memoryProstaglandin G/H synthase 2Homo sapiens (human)
regulation of blood pressureProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of cell population proliferationProstaglandin G/H synthase 2Homo sapiens (human)
response to xenobiotic stimulusProstaglandin G/H synthase 2Homo sapiens (human)
response to nematodeProstaglandin G/H synthase 2Homo sapiens (human)
response to fructoseProstaglandin G/H synthase 2Homo sapiens (human)
response to manganese ionProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of vascular endothelial growth factor productionProstaglandin G/H synthase 2Homo sapiens (human)
cyclooxygenase pathwayProstaglandin G/H synthase 2Homo sapiens (human)
bone mineralizationProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of prostaglandin biosynthetic processProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of fever generationProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of synaptic plasticityProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of synaptic transmission, dopaminergicProstaglandin G/H synthase 2Homo sapiens (human)
prostaglandin secretionProstaglandin G/H synthase 2Homo sapiens (human)
response to estradiolProstaglandin G/H synthase 2Homo sapiens (human)
response to lipopolysaccharideProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylationProstaglandin G/H synthase 2Homo sapiens (human)
response to vitamin DProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to heatProstaglandin G/H synthase 2Homo sapiens (human)
response to tumor necrosis factorProstaglandin G/H synthase 2Homo sapiens (human)
maintenance of blood-brain barrierProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of protein import into nucleusProstaglandin G/H synthase 2Homo sapiens (human)
hair cycleProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of apoptotic processProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of nitric oxide biosynthetic processProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of cell cycleProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of vasoconstrictionProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of smooth muscle contractionProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of smooth muscle contractionProstaglandin G/H synthase 2Homo sapiens (human)
decidualizationProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of smooth muscle cell proliferationProstaglandin G/H synthase 2Homo sapiens (human)
regulation of inflammatory responseProstaglandin G/H synthase 2Homo sapiens (human)
brown fat cell differentiationProstaglandin G/H synthase 2Homo sapiens (human)
response to glucocorticoidProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of calcium ion transportProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of synaptic transmission, glutamatergicProstaglandin G/H synthase 2Homo sapiens (human)
response to fatty acidProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to mechanical stimulusProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to lead ionProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to ATPProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to hypoxiaProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to non-ionic osmotic stressProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to fluid shear stressProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of transforming growth factor beta productionProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of cell migration involved in sprouting angiogenesisProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of fibroblast growth factor productionProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of brown fat cell differentiationProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of platelet-derived growth factor productionProstaglandin G/H synthase 2Homo sapiens (human)
cellular oxidant detoxificationProstaglandin G/H synthase 2Homo sapiens (human)
regulation of neuroinflammatory responseProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway in response to osmotic stressProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to homocysteineProstaglandin G/H synthase 2Homo sapiens (human)
response to angiotensinProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to organic cyclic compoundCytochrome P450 1B1Homo sapiens (human)
angiogenesisCytochrome P450 1B1Homo sapiens (human)
trabecular meshwork developmentCytochrome P450 1B1Homo sapiens (human)
DNA modificationCytochrome P450 1B1Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 1B1Homo sapiens (human)
nitric oxide biosynthetic processCytochrome P450 1B1Homo sapiens (human)
cell adhesionCytochrome P450 1B1Homo sapiens (human)
response to nutrientCytochrome P450 1B1Homo sapiens (human)
steroid metabolic processCytochrome P450 1B1Homo sapiens (human)
estrogen metabolic processCytochrome P450 1B1Homo sapiens (human)
negative regulation of cell population proliferationCytochrome P450 1B1Homo sapiens (human)
male gonad developmentCytochrome P450 1B1Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to oxidative stressCytochrome P450 1B1Homo sapiens (human)
toxin metabolic processCytochrome P450 1B1Homo sapiens (human)
positive regulation of vascular endothelial growth factor productionCytochrome P450 1B1Homo sapiens (human)
positive regulation of smooth muscle cell migrationCytochrome P450 1B1Homo sapiens (human)
sterol metabolic processCytochrome P450 1B1Homo sapiens (human)
arachidonic acid metabolic processCytochrome P450 1B1Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 1B1Homo sapiens (human)
collagen fibril organizationCytochrome P450 1B1Homo sapiens (human)
adrenal gland developmentCytochrome P450 1B1Homo sapiens (human)
negative regulation of cell migrationCytochrome P450 1B1Homo sapiens (human)
negative regulation of NF-kappaB transcription factor activityCytochrome P450 1B1Homo sapiens (human)
response to follicle-stimulating hormoneCytochrome P450 1B1Homo sapiens (human)
response to estradiolCytochrome P450 1B1Homo sapiens (human)
negative regulation of cell adhesion mediated by integrinCytochrome P450 1B1Homo sapiens (human)
benzene-containing compound metabolic processCytochrome P450 1B1Homo sapiens (human)
retinol metabolic processCytochrome P450 1B1Homo sapiens (human)
retinal metabolic processCytochrome P450 1B1Homo sapiens (human)
positive regulation of apoptotic processCytochrome P450 1B1Homo sapiens (human)
blood vessel endothelial cell migrationCytochrome P450 1B1Homo sapiens (human)
endothelial cell migrationCytochrome P450 1B1Homo sapiens (human)
estrous cycleCytochrome P450 1B1Homo sapiens (human)
positive regulation of translationCytochrome P450 1B1Homo sapiens (human)
positive regulation of angiogenesisCytochrome P450 1B1Homo sapiens (human)
positive regulation of receptor signaling pathway via JAK-STATCytochrome P450 1B1Homo sapiens (human)
membrane lipid catabolic processCytochrome P450 1B1Homo sapiens (human)
response to arsenic-containing substanceCytochrome P450 1B1Homo sapiens (human)
blood vessel morphogenesisCytochrome P450 1B1Homo sapiens (human)
retinal blood vessel morphogenesisCytochrome P450 1B1Homo sapiens (human)
ganglion developmentCytochrome P450 1B1Homo sapiens (human)
cellular response to hydrogen peroxideCytochrome P450 1B1Homo sapiens (human)
cellular response to cAMPCytochrome P450 1B1Homo sapiens (human)
cellular response to tumor necrosis factorCytochrome P450 1B1Homo sapiens (human)
cellular response to luteinizing hormone stimulusCytochrome P450 1B1Homo sapiens (human)
cellular response to cortisol stimulusCytochrome P450 1B1Homo sapiens (human)
cellular response to progesterone stimulusCytochrome P450 1B1Homo sapiens (human)
response to dexamethasoneCytochrome P450 1B1Homo sapiens (human)
endothelial cell-cell adhesionCytochrome P450 1B1Homo sapiens (human)
response to indole-3-methanolCytochrome P450 1B1Homo sapiens (human)
cellular response to toxic substanceCytochrome P450 1B1Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 1B1Homo sapiens (human)
response to 3-methylcholanthreneCytochrome P450 1B1Homo sapiens (human)
regulation of reactive oxygen species metabolic processCytochrome P450 1B1Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCytochrome P450 1B1Homo sapiens (human)
positive regulation of DNA biosynthetic processCytochrome P450 1B1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (27)

Processvia Protein(s)Taxonomy
monooxygenase activityCytochrome P450 1A1Homo sapiens (human)
iron ion bindingCytochrome P450 1A1Homo sapiens (human)
protein bindingCytochrome P450 1A1Homo sapiens (human)
arachidonic acid monooxygenase activityCytochrome P450 1A1Homo sapiens (human)
oxidoreductase activityCytochrome P450 1A1Homo sapiens (human)
oxidoreductase activity, acting on diphenols and related substances as donorsCytochrome P450 1A1Homo sapiens (human)
flavonoid 3'-monooxygenase activityCytochrome P450 1A1Homo sapiens (human)
oxygen bindingCytochrome P450 1A1Homo sapiens (human)
enzyme bindingCytochrome P450 1A1Homo sapiens (human)
heme bindingCytochrome P450 1A1Homo sapiens (human)
Hsp70 protein bindingCytochrome P450 1A1Homo sapiens (human)
demethylase activityCytochrome P450 1A1Homo sapiens (human)
Hsp90 protein bindingCytochrome P450 1A1Homo sapiens (human)
aromatase activityCytochrome P450 1A1Homo sapiens (human)
vitamin D 24-hydroxylase activityCytochrome P450 1A1Homo sapiens (human)
estrogen 16-alpha-hydroxylase activityCytochrome P450 1A1Homo sapiens (human)
estrogen 2-hydroxylase activityCytochrome P450 1A1Homo sapiens (human)
long-chain fatty acid omega-hydroxylase activityCytochrome P450 1A1Homo sapiens (human)
hydroperoxy icosatetraenoate dehydratase activityCytochrome P450 1A1Homo sapiens (human)
long-chain fatty acid omega-1 hydroxylase activityCytochrome P450 1A1Homo sapiens (human)
peroxidase activityProstaglandin G/H synthase 1Homo sapiens (human)
prostaglandin-endoperoxide synthase activityProstaglandin G/H synthase 1Homo sapiens (human)
protein bindingProstaglandin G/H synthase 1Homo sapiens (human)
heme bindingProstaglandin G/H synthase 1Homo sapiens (human)
metal ion bindingProstaglandin G/H synthase 1Homo sapiens (human)
oxidoreductase activity, acting on single donors with incorporation of molecular oxygen, incorporation of two atoms of oxygenProstaglandin G/H synthase 1Homo sapiens (human)
peroxidase activityProstaglandin G/H synthase 2Homo sapiens (human)
prostaglandin-endoperoxide synthase activityProstaglandin G/H synthase 2Homo sapiens (human)
protein bindingProstaglandin G/H synthase 2Homo sapiens (human)
enzyme bindingProstaglandin G/H synthase 2Homo sapiens (human)
heme bindingProstaglandin G/H synthase 2Homo sapiens (human)
protein homodimerization activityProstaglandin G/H synthase 2Homo sapiens (human)
metal ion bindingProstaglandin G/H synthase 2Homo sapiens (human)
oxidoreductase activity, acting on single donors with incorporation of molecular oxygen, incorporation of two atoms of oxygenProstaglandin G/H synthase 2Homo sapiens (human)
monooxygenase activityCytochrome P450 1B1Homo sapiens (human)
iron ion bindingCytochrome P450 1B1Homo sapiens (human)
protein bindingCytochrome P450 1B1Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 1B1Homo sapiens (human)
heme bindingCytochrome P450 1B1Homo sapiens (human)
aromatase activityCytochrome P450 1B1Homo sapiens (human)
estrogen 16-alpha-hydroxylase activityCytochrome P450 1B1Homo sapiens (human)
hydroperoxy icosatetraenoate dehydratase activityCytochrome P450 1B1Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, NAD(P)H as one donor, and incorporation of one atom of oxygenCytochrome P450 1B1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (15)

Processvia Protein(s)Taxonomy
mitochondrial inner membraneCytochrome P450 1A1Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 1A1Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 1A1Homo sapiens (human)
photoreceptor outer segmentProstaglandin G/H synthase 1Homo sapiens (human)
cytoplasmProstaglandin G/H synthase 1Homo sapiens (human)
endoplasmic reticulum membraneProstaglandin G/H synthase 1Homo sapiens (human)
Golgi apparatusProstaglandin G/H synthase 1Homo sapiens (human)
intracellular membrane-bounded organelleProstaglandin G/H synthase 1Homo sapiens (human)
extracellular exosomeProstaglandin G/H synthase 1Homo sapiens (human)
cytoplasmProstaglandin G/H synthase 1Homo sapiens (human)
neuron projectionProstaglandin G/H synthase 1Homo sapiens (human)
nuclear inner membraneProstaglandin G/H synthase 2Homo sapiens (human)
nuclear outer membraneProstaglandin G/H synthase 2Homo sapiens (human)
cytoplasmProstaglandin G/H synthase 2Homo sapiens (human)
endoplasmic reticulumProstaglandin G/H synthase 2Homo sapiens (human)
endoplasmic reticulum lumenProstaglandin G/H synthase 2Homo sapiens (human)
endoplasmic reticulum membraneProstaglandin G/H synthase 2Homo sapiens (human)
caveolaProstaglandin G/H synthase 2Homo sapiens (human)
neuron projectionProstaglandin G/H synthase 2Homo sapiens (human)
protein-containing complexProstaglandin G/H synthase 2Homo sapiens (human)
neuron projectionProstaglandin G/H synthase 2Homo sapiens (human)
cytoplasmProstaglandin G/H synthase 2Homo sapiens (human)
mitochondrionCytochrome P450 1B1Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 1B1Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 1B1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (54)

Assay IDTitleYearJournalArticle
AID1183067Antifungal activity against Candida kefyr clinical isolate assessed as growth inhibition after 48 hrs by broth microdilution method2014Journal of natural products, Jul-25, Volume: 77, Issue:7
Antifungal activity of resveratrol derivatives against Candida species.
AID330495Agonist activity at PPARalpha in rat H4IIEC3 cells assessed as luciferase activity 100 uM after 24 hrs2008Bioorganic & medicinal chemistry, Apr-01, Volume: 16, Issue:7
Design, synthesis, biological evaluation and docking studies of pterostilbene analogs inside PPARalpha.
AID1183070Antifungal activity against Candida norvegensis clinical isolate assessed as growth inhibition after 48 hrs by broth microdilution method2014Journal of natural products, Jul-25, Volume: 77, Issue:7
Antifungal activity of resveratrol derivatives against Candida species.
AID1352496Neuroprotective activity against H2O2-induced oxidative stress in human SH-SY5Y cells assessed as cell viability at 1 to 10 uM after 24 hrs by MTT assay relative to control2018European journal of medicinal chemistry, Feb-25, Volume: 146Alkylated resveratrol prodrugs and metabolites as potential therapeutics for neurodegenerative diseases.
AID1352499Inhibition of LPS-induced IL-6 production in rat RAW264.7 cells at 10 uM after 24 hrs by ELISA2018European journal of medicinal chemistry, Feb-25, Volume: 146Alkylated resveratrol prodrugs and metabolites as potential therapeutics for neurodegenerative diseases.
AID1183068Antifungal activity against Candida krusei ATCC 6258 assessed as growth inhibition after 48 hrs by broth microdilution method2014Journal of natural products, Jul-25, Volume: 77, Issue:7
Antifungal activity of resveratrol derivatives against Candida species.
AID1452982Inhibition of recombinant human CYP1A1 expressed in supersomes coexpressing NADPH-CYP reductase using 7-ethoxyresorufin as substrate after 15 mins in presence of NADP+ by Lineweaver-Burk plot analysis2017European journal of medicinal chemistry, Jul-28, Volume: 135Inhibitors of cytochrome P450 (CYP) 1B1.
AID1183064Antifungal activity against Candida glabrata ATCC 90030 assessed as growth inhibition after 48 hrs by broth microdilution method2014Journal of natural products, Jul-25, Volume: 77, Issue:7
Antifungal activity of resveratrol derivatives against Candida species.
AID1452983Inhibition of recombinant human CYP1B1 expressed in supersomes coexpressing NADPH-CYP reductase using 7-ethoxyresorufin as substrate after 15 mins in presence of NADP+ by Lineweaver-Burk plot analysis2017European journal of medicinal chemistry, Jul-28, Volume: 135Inhibitors of cytochrome P450 (CYP) 1B1.
AID146551In vitro growth inhibition of NCI-H460 (human non-small cell lung carcinoma) cell line.2002Journal of medicinal chemistry, Jun-06, Volume: 45, Issue:12
Antineoplastic agents. 465. Structural modification of resveratrol: sodium resverastatin phosphate.
AID1467689Inhibition of human TRPA1 expressed in HEK293 cells assessed as decrease in AITC-induced calcium influx at 30 uM preincubated for 6 mins followed by AITC addition measured for 1 min by Fluo-4 dye-based assay relative to resveratrol2017Bioorganic & medicinal chemistry letters, 07-15, Volume: 27, Issue:14
Synthesis of resveratrol derivatives as new analgesic drugs through desensitization of the TRPA1 receptor.
AID94870In vitro growth inhibition of KM20L2 cell line.2002Journal of medicinal chemistry, Jun-06, Volume: 45, Issue:12
Antineoplastic agents. 465. Structural modification of resveratrol: sodium resverastatin phosphate.
AID294477Induction of quinone reductase in mouse mutant Hepa 1c1c7c1 cells at 12.5 uM after 24 hrs relative to control2007European journal of medicinal chemistry, Jun, Volume: 42, Issue:6
Quinone reductase induction activity of methoxylated analogues of resveratrol.
AID57707In vitro growth inhibition of DU-145 (human prostate carcinoma) cell line.2002Journal of medicinal chemistry, Jun-06, Volume: 45, Issue:12
Antineoplastic agents. 465. Structural modification of resveratrol: sodium resverastatin phosphate.
AID294469Cytotoxicity against mouse Hepa 1c1c7 cells assessed as cell viability at 12.5 uM after 24 hrs by MTT assay2007European journal of medicinal chemistry, Jun, Volume: 42, Issue:6
Quinone reductase induction activity of methoxylated analogues of resveratrol.
AID510869Cytotoxicity against human Caco-2 cells after 3 days by [3H]thymidine incorporation assay2010European journal of medicinal chemistry, Sep, Volume: 45, Issue:9
In vitro and in vivo studies on stilbene analogs as potential treatment agents for colon cancer.
AID1352500Toxicity in 3 hrs post fertilized zebra fish AB embryo after 93 hrs2018European journal of medicinal chemistry, Feb-25, Volume: 146Alkylated resveratrol prodrugs and metabolites as potential therapeutics for neurodegenerative diseases.
AID1183062Antifungal activity against Candida dubliniensis ATCC MYA-646 assessed as growth inhibition after 48 hrs by broth microdilution method2014Journal of natural products, Jul-25, Volume: 77, Issue:7
Antifungal activity of resveratrol derivatives against Candida species.
AID40024In vitro growth inhibition of BXPC-3 (human pancreatic adenocarcinoma) cell line.2002Journal of medicinal chemistry, Jun-06, Volume: 45, Issue:12
Antineoplastic agents. 465. Structural modification of resveratrol: sodium resverastatin phosphate.
AID150946In vitro inhibition of P388 (murine leukemia) cell proliferation.2002Journal of medicinal chemistry, Jun-06, Volume: 45, Issue:12
Antineoplastic agents. 465. Structural modification of resveratrol: sodium resverastatin phosphate.
AID370919Inhibition of COX12009Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3
Synthesis and biological evaluation of a library of resveratrol analogues as inhibitors of COX-1, COX-2 and NF-kappaB.
AID1183069Antifungal activity against Candida lusitaniae CBS 6936 assessed as growth inhibition after 48 hrs by broth microdilution method2014Journal of natural products, Jul-25, Volume: 77, Issue:7
Antifungal activity of resveratrol derivatives against Candida species.
AID134178Compound (at 30 uM) was tested for inhibition against nitric oxide production in LPS-activated mouse peritoneal macrophages2000Bioorganic & medicinal chemistry letters, Feb-21, Volume: 10, Issue:4
Effects of stilbene constituents from rhubarb on nitric oxide production in lipopolysaccharide-activated macrophages.
AID370920Inhibition of COX22009Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3
Synthesis and biological evaluation of a library of resveratrol analogues as inhibitors of COX-1, COX-2 and NF-kappaB.
AID1374190Estrogenic activity at ERalpha/ERbeta (unknown origin) expressed in human HepG2 cells co-expressing ERE-dependent promoter assessed as increase in ER-mediated transcriptional activation at 10 uM incubated for 24 hrs by luciferase reporter gene assay relat2018Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4
Estrogenic activity of constituents from the rhizomes of Rheum undulatum Linné.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID132502Compound was tested for inhibitory activity against nitric oxide production in LPS-activated mouse peritoneal macrophages (*,showed cytotoxicity at 100 uM)2000Bioorganic & medicinal chemistry letters, Feb-21, Volume: 10, Issue:4
Effects of stilbene constituents from rhubarb on nitric oxide production in lipopolysaccharide-activated macrophages.
AID1183065Antifungal activity against Candida guilliermondii ATCC 6260 assessed as growth inhibition after 48 hrs by broth microdilution method2014Journal of natural products, Jul-25, Volume: 77, Issue:7
Antifungal activity of resveratrol derivatives against Candida species.
AID510868Cytotoxicity against human HT-29 cells after 3 days by [3H]thymidine incorporation assay2010European journal of medicinal chemistry, Sep, Volume: 45, Issue:9
In vitro and in vivo studies on stilbene analogs as potential treatment agents for colon cancer.
AID255902Inhibitory concentration required for antiproliferative activity against human MDA-MB-231 cells2005Journal of medicinal chemistry, Nov-03, Volume: 48, Issue:22
Synthesis of a resveratrol analogue with high ceramide-mediated proapoptotic activity on human breast cancer cells.
AID294474Induction of quinone reductase activity in mouse Hepa 1c1c7 cells at 12.5 uM after 24 hrs relative to control2007European journal of medicinal chemistry, Jun, Volume: 42, Issue:6
Quinone reductase induction activity of methoxylated analogues of resveratrol.
AID568507Induction of NQO1 activity in mouse Hepa1c1c7 cells assessed as concentration required to twofold increase of NQO1 activity at IC50 concentration relative to control2011Bioorganic & medicinal chemistry letters, Feb-01, Volume: 21, Issue:3
Methoxylation of resveratrol: effects on induction of NAD(P)H quinone-oxidoreductase 1 (NQO1) activity and growth inhibitory properties.
AID1183072Antifungal activity against Candida tropicalis ATCC MYA-3404/T1 assessed as growth inhibition after 48 hrs by broth microdilution method2014Journal of natural products, Jul-25, Volume: 77, Issue:7
Antifungal activity of resveratrol derivatives against Candida species.
AID356481ABTS radical scavenging activity assessed as trolox equivalent antioxidant capacity after 10 mins2003Journal of natural products, Sep, Volume: 66, Issue:9
Resveratrol and two monomethylated stilbenes from Israeli Rumex bucephalophorus and their antioxidant potential.
AID1352495Cytotoxicity against human SH-SY5Y cells at 10 uM after 24 hrs by MTT assay2018European journal of medicinal chemistry, Feb-25, Volume: 146Alkylated resveratrol prodrugs and metabolites as potential therapeutics for neurodegenerative diseases.
AID200787In vitro growth inhibition of central nervous system SF-268 cell line.2002Journal of medicinal chemistry, Jun-06, Volume: 45, Issue:12
Antineoplastic agents. 465. Structural modification of resveratrol: sodium resverastatin phosphate.
AID1374189Estrogenic activity at ERalpha/ERbeta (unknown origin) expressed in human HepG2 cells co-expressing ERE-dependent promoter assessed as increase in ER-mediated transcriptional activation at 1 uM incubated for 24 hrs by luciferase reporter gene assay relati2018Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4
Estrogenic activity of constituents from the rhizomes of Rheum undulatum Linné.
AID103219Cell growth inhibition of breast MCF-7 cells, expressed as 50% reduction in the net protein increase2002Journal of medicinal chemistry, Jun-06, Volume: 45, Issue:12
Antineoplastic agents. 465. Structural modification of resveratrol: sodium resverastatin phosphate.
AID311534Antibacterial activity against Helicobacter pylori ATCC 43504 by agar dilution method2007Journal of natural products, Oct, Volume: 70, Issue:10
Anti-Helicobacter pylori and thrombin inhibitory components from Chinese dragon's blood, Dracaena cochinchinensis.
AID568508Cytotoxicity against mouse Hepa-1c1c7 cells after 24 hrs by MTT assay2011Bioorganic & medicinal chemistry letters, Feb-01, Volume: 21, Issue:3
Methoxylation of resveratrol: effects on induction of NAD(P)H quinone-oxidoreductase 1 (NQO1) activity and growth inhibitory properties.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1183071Antifungal activity against Candida parapsilosis ATCC 22019 assessed as growth inhibition after 48 hrs by broth microdilution method2014Journal of natural products, Jul-25, Volume: 77, Issue:7
Antifungal activity of resveratrol derivatives against Candida species.
AID1183063Antifungal activity against Candida famata VKMY-9 assessed as growth inhibition after 48 hrs by broth microdilution method2014Journal of natural products, Jul-25, Volume: 77, Issue:7
Antifungal activity of resveratrol derivatives against Candida species.
AID355284Inhibition of adenosine diphosphate-induced platelet aggregation in human platelet-rich plasma1997Journal of natural products, Nov, Volume: 60, Issue:11
Isolation, synthesis, and antiplatelet aggregation activity of resveratrol 3-O-beta-D-glucopyranoside and related compounds.
AID228863Antioxidant activity as the effective concentration to achieve 50% bioeffectivity value of 2,2-diphenyl-1-picrylhydrazyl radical (DPPH)2003Bioorganic & medicinal chemistry letters, Jun-02, Volume: 13, Issue:11
Density functional theory calculations for resveratrol.
AID1183061Antifungal activity against Candida albicans SC5314 ATCC MYA-2876 assessed as growth inhibition after 48 hrs by broth microdilution method2014Journal of natural products, Jul-25, Volume: 77, Issue:7
Antifungal activity of resveratrol derivatives against Candida species.
AID37425Inhibitory activity against yeast alpha-glucosidase; active2004Bioorganic & medicinal chemistry letters, Jul-16, Volume: 14, Issue:14
Yeast and mammalian alpha-glucosidase inhibitory constituents from Himalayan rhubarb Rheum emodi Wall.ex Meisson.
AID355281Inhibition of collagen-induced platelet aggregation in human platelet-rich plasma1997Journal of natural products, Nov, Volume: 60, Issue:11
Isolation, synthesis, and antiplatelet aggregation activity of resveratrol 3-O-beta-D-glucopyranoside and related compounds.
AID1183066Antifungal activity against Candida inconspicua clinical isolate assessed as growth inhibition after 48 hrs by broth microdilution method2014Journal of natural products, Jul-25, Volume: 77, Issue:7
Antifungal activity of resveratrol derivatives against Candida species.
AID1467690Agonist activity at human TRPA1 expressed in HEK293 cells assessed as induction of calcium influx at 30 uM after 6 mins by Fluo-4 dye-based assay relative to AITC2017Bioorganic & medicinal chemistry letters, 07-15, Volume: 27, Issue:14
Synthesis of resveratrol derivatives as new analgesic drugs through desensitization of the TRPA1 receptor.
AID294468ABTS radical scavenging activity assessed as trolox equivalent antioxidant capacity2007European journal of medicinal chemistry, Jun, Volume: 42, Issue:6
Quinone reductase induction activity of methoxylated analogues of resveratrol.
AID1352498Inhibition of LPS-induced TNF-alpha production in rat RAW264.7 cells at 10 uM after 24 hrs by ELISA2018European journal of medicinal chemistry, Feb-25, Volume: 146Alkylated resveratrol prodrugs and metabolites as potential therapeutics for neurodegenerative diseases.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (33)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's2 (6.06)18.2507
2000's13 (39.39)29.6817
2010's17 (51.52)24.3611
2020's1 (3.03)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.49

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.49 (24.57)
Research Supply Index3.53 (2.92)
Research Growth Index5.02 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.49)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (6.06%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other31 (93.94%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]